Imunon
Update in progressIMNN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Imunon, Inc. is a clinical-stage U.S. biotechnology company developing immunotherapies and vaccines. Its lead program, IMNN-001, is a DNA-based immunotherapy in Phase 3 for localized treatment of advanced ovarian cancer, with IND-enabling work for colorectal and pancreatic cancers and discovery efforts for glioblastoma. IMNN-101, a COVID-19 booster, has completed Phase 1. The company also advances non-viral DNA platforms, TheraPlas and PlaCCine. Formerly Celsion, renamed in 2022. Founded 1982, based in Lawrenceville, NJ.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Stacy R. Lindborg Ph.D.
- Founded1982
- Employees20
- Websiteimunon.com
Identifiers
- ISINUS15117N6022
- FIGIBBG000BJJGT8
- CUSIP15117N701
- CIK0000749647